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Abstract 18 
Over 200 million people worldwide suffer from malaria every year, a disease 19 
that causes 584,000 deaths annually. In recent years, significant improvements have 20 
been achieved on the treatment of severe malaria, with intravenous artesunate proving 21 
superior to quinine. However, mortality remains high at 8% in children and 15% in 22 
adults in clinical trials, and even worse in the case of cerebral malaria (18% and 30%, 23 
respectively). Moreover, some individuals who do not succumb to severe malaria 24 
present long-term cognitive deficits. These observations indicate that strategies focused 25 
only on parasite killing fail to prevent neurological complications and deaths associated 26 
with severe malaria, possibly because clinical complications are associated in part with 27 
a cerebrovascular dysfunction. Consequently, different adjunctive therapies aimed at 28 
modulating malaria pathophysiological processes are currently being tested. However, 29 
none of these therapies has shown unequivocal evidence in improving patients’ clinical 30 
status. Recently, key studies have shown that gaseous therapies based mainly on nitric 31 
oxide (NO), carbon monoxide (CO) and hyperbaric (pressurized) oxygen (HBO) alter 32 
vascular endothelium dysfunction and modulate host immune response to infection. 33 
Considering gaseous administration as a promising adjunctive treatment against severe 34 
malaria cases, we review here the pathophysiological mechanisms and the 35 
immunological aspects of such therapies. 36 
 37 
38 
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Introduction 39 
 Malaria exerts a heavy burden over human populations, with an estimated 124–40 
283 million cases and 584,000 deaths in 2013 (1). Currently, intravenous artesunate is 41 
the treatment of choice in severe malaria cases in children and adults (2, 3). However, 42 
despite the efficacy of intravenous artesunate, mortality from severe malaria in general 43 
and from cerebral malaria (CM) in particular remains high, at 18% for African children 44 
and 30% for adults in Southeast Asia (2, 3). In addition, 11% of children who survive 45 
CM show severe neurological deficits and up to 25% can maintain long-term cognitive 46 
deficits (4-8). Therefore, strategies focusing only on parasite killing may not be 47 
sufficient to prevent neurological complications and deaths related to severe malaria.  48 
Accordingly, adjunctive therapies – defined as therapies administered in 49 
combination with anti-parasitic drugs that modify pathophysiological processes caused 50 
by malaria – are being sought in order to mitigate complications caused by severe 51 
malaria (9). Considering the fact that currently administered antimalarial drugs often 52 
take 12-18 hours to kill parasites, adjunctive therapies could reduce the risk of 53 
neurocognitive sequelae and mortality, particularly in patients with CM (10). 54 
Different adjunctive therapies have been or are being tested, including 55 
treatments aimed at modulation of the immune response to infection (dexamethasone, 56 
intravenous immunoglobulin); reduction of iron burden; reduction of oxidative stress; 57 
modulation of prothrombotic state; reduction of parasitemia (blood transfusion); among 58 
others (reviewed elsewhere) (10, 11). However, none of these adjunctive treatments has 59 
shown unequivocal evidence of improvement for patients in clinical trials and therefore 60 
none of them can be definitely recommended as a treatment strategy (10, 11). Thus, 61 
pursuing new adjunctive therapies for malaria remains a research priority. 62 
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It is in this scenario that the gas-based therapies for malaria arise. The study of 63 
administration of gas therapies has advanced in some areas, such as hyperbaric 64 
(pressurized) oxygen (HBO) for complicated wound healing (12-14) and nitric oxide 65 
(NO) for acute respiratory distress syndrome (15), although not without controversy 66 
(16, 17). Nevertheless, the use of gaseous therapy for malaria is incipient. At the 67 
moment, only two phase II clinical trials have been completed, both examining the 68 
effect of NO administration in children with severe malaria (18, 19). Nevertheless, some 69 
in vitro and in vivo studies – using the Experimental Cerebral Malaria (ECM) murine 70 
model – have shed light on the topic and opened perspectives for adjunctive therapies in 71 
malaria. ECM is the result of the infection of susceptible mouse strains, such as 72 
C57BL/6 and CBA, with Plasmodium berghei ANKA (PbA) strain (20). The relevance 73 
of this model is a matter of heated debate which is discussed in depth elsewhere (21-74 
24). Of critical importance is the fact that in both human and murine severe malaria 75 
ischemia/hypoxia resulting from hypoperfusion play a key role in pathogenesis and in 76 
both cases hypoperfusion results from vascular occlusion and dysfunction. Human 77 
severe malaria findings such as retinal hypoperfusion (25), impaired reactive 78 
hyperemia-peripheral arterial tonometry index (RH-PAT, a measurement of reactive 79 
vasodilation) (26), low NO bioavailability (26), increased levels of plasma cell-free 80 
hemoglobin (27), elevated ADMA to arginine plasma ratios (28, 29) and low levels of 81 
plasma angiopoietin-1 (30) are closely mimicked in PbA-infected mice displaying 82 
severe malaria (31-34). Since ischemia and vascular dysfunction are the prime targets of 83 
gaseous therapies, the murine model of severe malaria may work as a reliable surrogate 84 
to address these issues. However, the limitations of any experimental model need to be 85 
considered, with findings requiring subsequent confirmation in human studies. Having 86 
these considerations in mind, and due to the obvious restrictions imposed to studies in 87 
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humans, experimental models may represent valuable sources of insights and 88 
establishing proof-of-concepts for the discovery of mechanisms of pathogenesis and 89 
novel therapeutic targets. Herein, we review the state-of-the-art of the study of Carbon 90 
Monoxide (CO), NO and HBO as adjunctive therapies for malaria.  91 
 92 
Carbon Monoxide (CO)  93 
CO is physiologically produced as a byproduct of the degradation of heme, in a 94 
reaction catalyzed by heme-oxygenase 1 (HO-1), also producing Fe2+ and biliverdin 95 
(35). Although widely known for its toxicity due to the high affinity binding of 96 
hemoglobin, CO has drawn scientific attention for its role as a signaling molecule in the 97 
gastrointestinal tract, a paracrine mediator of smooth muscle hyperpolarization and as 98 
an immunomodulatory effector (35-37). The immune actions of CO take part in the 99 
‘immunological web’ of HO-1, the inducible form of heme-oxygenase, whose 100 
expression is up regulated in situations of cellular exposure to oxidant agents, pathogens 101 
and other stressors (35). The co-localization of HO-1 expression and vascular lesions in 102 
brains of patients that died from CM evidences HO-1 induction (38), albeit it does not 103 
necessarily mean increased or sufficient enzymatic activity (39). In ECM, PbA-infected 104 
BALB/c mice exhibited a higher expression of the Heme-oxygenase-1 gene (Hmox-1) 105 
and HO-1 than C57BL/6 mice, and were less likely to die of ECM (40). Furthermore, 106 
deletion of Hmox-1 rendered BALB/c mice susceptible to death by ECM (40). The 107 
protective action of the augmented expression of HO-1 is believed to take place through 108 
CO production and its binding of cell-free hemoglobin (40-42). In malaria, cell-free 109 
hemoglobin is produced due to hemolysis and its degradation leads to the formation of 110 
free heme, a highly oxidant molecule supposed to be a key mediator of the blood-brain 111 
barrier (BBB) dysfunction, a hallmark of CM (43, 44). In this regard, Pena et al (41) 112 
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have developed a CO-releasing molecule (CO-RM) that fully protected mice from death 113 
due to ECM when administered before the onset of symptoms, preventing inflammation 114 
and BBB disruption. The use of the CO-RM in combination with artesunate improved 115 
survival in 83%, when compared to artesunate alone, indicating the potential of this 116 
molecule to work as an adjunctive therapy. 117 
Nevertheless, the effect of CO and HO-1 in CM is a matter of debate. Studies 118 
from Myanmar, Angola and Gambia have found an association between shorter (GT)n 119 
repeat polymorphisms in the Hmox-1 promoter region – correlated with higher 120 
expression of the gene and higher levels of HO-1 in peripheral blood – and the 121 
incidence of severe malaria (45-47). The authors of the Gambian study argue that while 122 
this observation may simply reflect an adequate but insufficient response, the higher 123 
induction of HO-1 in patients with shorter (GT)n repeat alleles indicates that levels of 124 
HO-1 above a certain threshold might directly participate in the disease pathogenesis 125 
(48). Such deleterious effects might involve oxidative pathways via activation of 126 
neutrophil oxidative burst (46) and release of iron (48). These findings highlight a 127 
problem in experimental models dealing with CO and HO-1 in malaria as inbred mice 128 
lack the variability of HO-1 (GT)n repeat polymorphism (49).  129 
Considering that in ECM the liver phase of malarial infection is skipped (40, 41, 130 
50), discrepancies in HO-1 levels between the mouse model and human infections 131 
might occur (51). For example, Epiphanio et al., 2008, found that when Hmox-1-/- mice 132 
were infected with sporozoites, instead of directly inoculated with blood-stage parasites, 133 
infection failed to develop, and that inhalation of CO by Hmox-1+/+ mice in this setting, 134 
led to 4-fold increase in P. berghei liver infection (51). Given that malaria is diagnosed 135 
during the blood phase of infection, HO-1/CO-based therapeutic approaches possibly 136 
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would not face the dilemma of increasing parasite load in P. falciparum infection, but 137 
the same is not warranted for species that produce hypnozoites, such as P. vivax.  138 
A major concern, however, for the application of CO based therapies is the gas 139 
intrinsic toxicity. CO poisoning is a leading cause of unintentional poisoning (52), and 140 
carboxyhemoglobin (COHb) levels as low as 3% are indicative of exposition in non-141 
smokers. Toxicity from free-hemoglobin released during malaria may be prevented by 142 
CO’s ability to bind hemoglobin, which is the exact same mechanism that drives its 143 
toxicity. Yeo et al (53) have described an association between COHb levels and severity 144 
in Indonesian adults with malaria, however no such association was found for Kenyan 145 
children (39). While in the former COHb might have been generally overestimated, 146 
there was a significant increase in COHb levels from healthy controls in moderately 147 
severe and severe malaria. While the smaller but significant increase in COHb in 148 
patients with moderately severe malaria might indeed reflect a protective effect from an 149 
adequate increase in HO-1 activity, further increases in COHb seem insufficient or 150 
harmful (46, 53). Besides a possible harmful effect of HO-1 super activation, induction 151 
of COHb leads to a decrease in blood oxygen carrying capacity. In severe malaria 152 
patients hemoglobin levels are already reduced, imposing serious risks and limitations 153 
for the use of CO as an adjunctive therapy (53). 154 
 155 
Nitric Oxide (NO) 156 
NO plays physiological roles in neuronal and vascular cells, regulating 157 
vasodilation and blood pressure, among other biological effects. It is produced by the 158 
activity of enzymes known as NO synthase (NOS) whose substrates are the amino acid 159 
L-arginine and O2. Three NOS isoforms have been identified: neuronal (NOS1), 160 
inducible (NOS2) and endothelial (NOS3). Both NOS1 and NOS3 are calcium 161 
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dependent enzymes expressed constitutively whereas NOS2 is expressed in response to 162 
acute inflammatory stimuli (54). NO has been related to numerous pathological 163 
conditions including artery disease (55),  cerebrovascular stroke (56), sepsis (57) and 164 
ischemic injury (58). 165 
Reduced NO bioavailability has been reported in human malaria (59) and ECM 166 
(33) and this phenomenon could contribute to the development of disease by 167 
impairment of endothelial function and vascular perfusion as reviewed elsewhere (60). 168 
NO decreases the expression of endothelium activation markers and reduces the 169 
expression of adhesion molecules, such as ICAM-1 and P-selectin, resulting in 170 
decreased vascular permeability (61) and leukocyte and platelet adhesion (62).  171 
Autopsy of CM patients revealed the sequestration of infected red blood cells 172 
(iRBC) in the capillaries and post-capillary venules of multiple organs, suggesting a role 173 
for iRBC cytoadherence in the pathogenesis of severe malaria (61, 63, 64). NO 174 
exposure led to reduced iRBC adherence to endothelium under flow conditions in vitro 175 
(65) as well as a decreased biomass of infected erythrocytes on cerebral tissue in ECM 176 
(66). Thus, NO may play a role against CM via anti-adhesive effects. 177 
Mice with ECM show widespread cerebrovascular constriction, leading to 178 
marked ischemic hypoxia (67) and decreased blood flow (31) . In addition, pial vessels 179 
of mice with ECM show impaired NOS1- and NOS3-mediated vasodilatory response to 180 
pharmacological stimulation (68). Evidence of vascular dysfunction has been 181 
documented also in human CM, with the observation of retinal vascular occlusion, 182 
hypoperfusion and hemorrhage (25), and impaired vasodilation, along with low exhaled 183 
NO levels (26). Several factors are thought to contribute to low NO bioavailability, such 184 
as hypoargininemia (low plasma L-arginine concentration) (69), increased concentration 185 
of the NOS inhibitor and reduced expression of NOS (28, 59, 70).  186 
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Therefore, adjunctive therapies aimed at restoring NO levels were developed. In 187 
PbA-infected mice, treatment with the NO donor Dipropylenetriamine NONOate 188 
(DPTA-NO) prevented the neurological syndrome, with increased endothelial barrier 189 
integrity and protecting the brain tissue from extravasation and petechial hemorrhaging, 190 
but led to hypotension in mice (71). Treatment with S-nytrosylated glutathione (GSNO), 191 
an endogenous, physiological NO-donor, prevented ECM development while having 192 
milder effects on blood pressure (72). Glyceryl trinitrate (nitroglycerin, GTN) not only 193 
prevented ECM but also worked as adjunctive therapy with artemether, markedly 194 
increasing survival of mice with late-stage ECM compared to artemether alone (73). 195 
The benefit in survival was associated with reversal of cerebrovascular constriction, 196 
suggesting that the effect was due to improved brain perfusion. Finally, novel hybrid 197 
drugs combining dihydroartemisinin with NO donors were shown to be more effective 198 
than artemether in rescuing mice with ECM (74). The benefits of NO donors, such as 199 
the ones described above, have not yet been shown in human CM. 200 
An alternative form of NO treatment is the inhalation of NO (iNO), which is 201 
approved by FDA for the treatment of respiratory failure, hypoxia and pulmonary 202 
hypertension (75). During ECM, iNO treatment reduced the activation of endothelial 203 
cells, decreased the number of parasites in the brain, maintained BBB integrity and 204 
when combined with artesunate improved mice survival rates when compared to 205 
artesunate alone (66). However, it must be emphasized that mice were treated before the 206 
neurological syndrome was established. Given that iNO is used in the treatment of other 207 
diseases, with a well-established safety profile and low cost, along with positive results 208 
in animal models, it is an attractive option for clinical tests in malaria patients. Based on 209 
these advantages, two randomized phase II clinical trial in patients with severe malaria 210 
have been recently reported in Uganda (18, 19, 76). The first study compared 88 211 
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children who received iNO at 80 ppm with 92 children who received placebo (all 212 
subjects received artesunate IV) showed that iNO failed to reduce angiopoietin-2 (Ang-213 
2; a marker of endothelial dysfunction) levels and had no effect on mortality (18). 214 
Methemoglobinemia did develop in 25% of children in the treated group, but without 215 
sequelae. The second study compared 46 children receiving iNO at 80 ppm with 46 216 
children in the placebo group with similar results. Plasma levels of Ang-2 and 217 
inflammatory cytokines remained similar between groups, and there was no difference 218 
in mortality (19). Treatment with iNO resulted in increased levels of plasma nitrate, and 219 
methemoglobinemia developed, but without sequelae. The fact that iNO combined with 220 
artesunate did not result in a greater reduction of Ang-2 levels compared to artesunate 221 
alone in these trials indicates that a measurable biological effect on the endothelium was 222 
not achieved with this NO dose and route of administration (70, 71). A major potential 223 
limitation with iNO is that NO may not exert its expected effects systemically, rather 224 
being restricted to the lung endothelium. In such a scenario, rapid conversion of iNO to 225 
nitrate and other stable adducts may result in decreased levels of bioavailable NO, 226 
although pharmacological effects beyond the pulmonary vasculature have been reported 227 
in other studies in humans (77). The use of better, more reliable readouts of NO action 228 
in the systemic vasculature in these trials is imperative to ensure that it is being properly 229 
delivered. 230 
Infusion of L-arginine is another candidate for adjunctive treatment based on 231 
increasing NO levels. Patients with severe falciparum malaria treated with antimalarial 232 
drugs showed a correlation between increased levels of L-arginine and the improvement 233 
of endothelial function (78). Infusion of L-arginine improved NO bioavailability 234 
without significant adverse effects on vital signs (26). Despite these encouraging results, 235 
in patients with severe falciparum malaria infusion of L-arginine at low doses over 8 236 
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hours failed to change lactate clearance time and RH-PAT (79). However, this was a 237 
small pilot study, and as such was unpowered to show beneficial effects. 238 
Despite advances reported by NO therapy studies, the molecular mechanisms 239 
involved in induction of protection are not completely elucidated. Data from animal 240 
studies suggest its main effect takes place by restoring vascular tonus and hence 241 
reversing cerebral ischemia/hypoxia (68, 71). Recent research demonstrated in ECM 242 
that NO regulates Hmox-1 expression by a mechanism involving the transcription factor 243 
Nfr-2 and consequently CO production. The proposed mechanism is that CO prevents 244 
Hb oxidation and heme release while NO exerts a pro-oxidant effect, preventing 245 
activation, proliferation and expansion of T cells and thus inhibiting a deleterious 246 
response to malaria infection (50) (Figure 1a and 1b). However, this remains to be 247 
further confirmed for human disease. 248 
 249 
Hyperbaric Oxygen (HBO) 250 
The inhalation of oxygen (95%) at normobaric (1 atmosphere) conditions was 251 
found to be ineffective for the treatment of malaria (80), therefore an alternative form of 252 
O2 delivery, as a hyperbaric (pressurized) oxygen (HBO), has been developed. HBO is 253 
defined as a treatment of exposure to oxygen (100%) at a pressure greater than one 254 
atmosphere absolute (ATA) (81). It is the only treatment for decompression sickness 255 
(81), and is recommended for complicated wound healing (14). In addition, HBO is 256 
widely used as an adjunctive therapy in many conditions, such as diabetic ulcer healing, 257 
traumatic brain injury and ischemic stroke. However, recent meta-analysis of clinical 258 
trials for the latter three conditions found no conclusive evidence for benefit to the 259 
patient after HBO therapy (13, 82, 83).  260 
HBO treatment is relatively safe, (84, 85), and some studies have shown it has 261 
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anti-inflammatory activity (86-88). These features support further research into HBO 262 
treatment as an adjunctive therapy candidate for a wide range of diseases (89). 263 
Observations drawn from human studies suggest that HBO might be useful in the 264 
treatment of some bacterial and fungal infections, like purpura fulminans (90) and 265 
necrotizing fasciitis (91). However, only a few studies have investigated the application 266 
of HBO to protozoan infections (92, 93) including ECM (94, 95). 267 
Blanco and colleagues (94) demonstrated that HBO therapy was neuroprotective 268 
in ECM. In this study, HBO treatment prevented clinical signs and improved mortality 269 
of up to half of treated mice. HBO treatment decreased mRNA levels of IFN-γ, TNF-α 270 
and IL-10 and reduced sequestration of γδ and αβ CD4+ and CD8+ T lymphocytes in the 271 
brain, which supports its neuroprotective effect. In addition, HBO therapy prevented 272 
BBB dysfunction and hypothermia, and significantly decreased parasite burden of PbA-273 
infected mice as well as in mice infected with P. berghei-NK65 (non-ECM strain) (94). 274 
These data pointed to possibility for HBO as an adjunctive therapy for CM. However, a 275 
better understanding of the mechanisms involved in the protection of ECM by HBO is 276 
needed. Figure 1c summarizes current knowledge of mechanisms of pressurized O2 277 
treatment. 278 
 279 
Hydrogen sulfide (H2S) 280 
H2S is a gas produced endogenously as a byproduct of the metabolism of the 281 
amino acid L-cysteine which occurs via at least three enzymes: cystathionineβ-synthase, 282 
cystathione γ-lyase and 3-mercaptopyruvate sulfurtransferase. Labeled as a toxic gas, 283 
H2S has emerged as an important signaling molecule, a gastransmittor, influencing 284 
physiological and pathological processes (96-98). Its pleiotropic effect has been 285 
reported in inflammation, neuromodulation and apoptosis as reviewed by (99). 286 
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Protective effects of H2S were observed in animal models of atherosclerosis (100), 287 
shock (101), cardiac arrest (102) and cerebral ischemia (103). Fast and slow donors of 288 
H2S (NaHS and GYY4137 respectively) were tested in vitro against P. falciparum 289 
(3D7, PA and HB3) and were shown to inhibit parasitemia in a dose dependent manner 290 
(104). H2S acted against the parasite by directly altering its cellular metabolism. 291 
However, in vivo treatment did not prevent development of ECM or death of infected 292 
mice. This study indicated that H2S could contribute to protein thiolation and interfere 293 
with cellular redox balance but the mechanisms were not elucidated (Figure 1d). 294 
Although preliminary results with H2S have not shown exciting results against malaria 295 
in vivo, a reformulation of the H2S delivery system of with a prolonged half-life time 296 
may generate promising results, opening perspectives for its use as antimalarial therapy.  297 
 298 
Conclusion 299 
In spite of advances in malaria therapeutics, the morbidity and mortality rates 300 
attributable to CM are still high. Therefore, an adjunctive therapy preventing the 301 
complications, sequelae and deaths of CM patients is urgent. Gas-based therapies are an 302 
attractive complement for CM treatment, although the emphasis on the toxic properties 303 
of some of the gases discussed in this review may have limited their study. However, as 304 
more information about the physiological roles of these gases emerges, greater scientific 305 
interest builds on their research. NO is the most investigated among the gas-based 306 
therapies, nevertheless its beneficial effect is yet to be validated in human CM. The 307 
investigation of the pleiotropic activity of these molecules, which regulate a large 308 
number of biologic processes, is needed, considering that cerebral malaria is a 309 
multifactorial process. More intense research with these and other molecules with 310 
therapeutic potential are necessary to open perspectives to combat a disease that costs 311 
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hundreds of thousands of lives every year. 312 
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Figure Legend 704 
 705 
Figure 1. Effect of NO, CO, HBO and H2S on cerebral malaria. (a) NO and CO 706 
inhibit endothelial activation, decreasing expression of adhesive receptors and secretion 707 
of pro-inflammatory molecules. Consequently, sequestration of leukocytes and mature 708 
infected red blood cells (iRBC) is blocked, as well as BBB disruption triggered by 709 
perforin and granzyme released by CD8+ T cells. Pro-inflammatory molecules secreted 710 
by leukocytes may promote activation of platelets, which adhere to the endothelium and 711 
initiate coagulation process, a relevant event in cerebral malaria. Free-heme, a toxic 712 
agent generated from free Hb oxidation during hemolysis, reacts with NO and CO 713 
producing metha- and carboxy-Hb, respectively. Besides promoting vasodilation, NO 714 
also induces HO-1 expression with the involvement of the transcription factor nrf-2, and 715 
HO-1 breaks free heme forming endogenous CO. (b) Some results indicate that NO and 716 
CO lead an immunological tolerance to parasites inhibiting activation, proliferation and 717 
differentiation of T cells. (c) Hyperbaric oxygen protects mice from CM by decreasing 718 
pro-inflammatory cytokines levels and leukocytes sequestration in the brain of infected 719 
mice, which in turn, could increase microvascular blood flow, decreasing tissue 720 
hypoxia, and thus preventing BBB disruption. (d) H2S is harmful to parasites. 721 
Thiolation of parasite proteins alters cellular metabolism resulting in generation of 722 
ROS, which impair glycolysis and parasite respiration. 723 
MØ: monocyte. BBB: blood brain barrier. ROS: reactive oxygen species. 724 
 725 
 o
n
 July 13, 2017 by CO
NSO
L.CAPES-T299093
http://iai.asm
.org/
D
ow
nloaded from
 
Table 1.  Gaseous treatments for cerebral malaria.
Gaseous 
molecule 
Therapeutic delivery 
methods 
           Outcomes Clinical trials  
 
CO 
 
Inhaled CO  
 
 
 
 
Molecules releasing 
CO (CO-RM) 
 
Increased parasite load in 
liver (51). Prevented 
ECM syndrome and 
BBB disruption (40) 
 
Prevented ECM 
syndrome and death. 
Protected mice from ALI 
(41) 
 
 
___ 
 
 
 
 
 
___ 
 
NO Donor of NO: 
Dipropylenetriamine 
NONOate  
 
Donor of NO: GSNO 
(S-nytrosylated 
glutathione) 
 
 
Donor of NO: GTN 
(nitroglycerin) 
 
 
 
 
Artemisinin-NO-donor 
hybrid 
 
 
inhaled NO (iNO) 
 
 
 
 
 
L-arginine infusion 
Increased survival and 
protected BBB disruption 
in ECM (71) 
 
Prevented ECM 
syndrome and death. 
Decreased inflammation 
and edema in ECM (72) 
 
Protected mice from 
ECM and when 
combined with 
artemether increased 
survival (73)  
 
Antiplasmodial activity. 
Rescue mice from ECM 
(74). 
 
Increased survival and 
reduced systemic 
inflammation in mice 
infected with PbA (66) 
 
 
___ 
 
___ 
 
 
 
___ 
 
 
 
 
 
___ 
 
 
 
 
___ 
 
 
 
Safe but with no effect on 
mortality in children with severe 
malaria (iNO at 80 ppm) (18, 
19, 76) 
 
 
In severe falciparum malaria it 
showed no increase of NO 
endothelial production (79) 
 
O2 
 
Hyperbaric oxygen 
(HBO) 
 
Protected mice from 
cerebral malaria, 
decreasing clinical 
symptoms and mortality 
rate (94) 
 
___ 
H2S H2S donors Antiplasmodial activity. No effect on ECM at 
dose tested (104). 
___ 
BBB: blood-brain barrier; ALI: acute lung injury. 
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